Medication Development in Alcoholism: Investigating PPAR Agonists
NCT ID: NCT02158273
Last Updated: 2017-06-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2014-05-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
NCT01548417
A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II
NCT02707055
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
NCT05107765
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322
Medication Development in Alcoholism: Apremilast Versus Placebo
NCT03175549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TRICOR (fenofibrate)
TRICOR (fenofibrate)
145 mg/day, oral pill, 9 days
Sugar Pill
Sugar Pill
145 mg/day, oral pill, 9 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sugar Pill
145 mg/day, oral pill, 9 days
TRICOR (fenofibrate)
145 mg/day, oral pill, 9 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets DSM-V criteria for Alcohol Use Disorder ≥ moderate severity and DSM-IV criteria for current alcohol dependence
* Subjects will not be seeking treatment because the medication studies are not treatment trials
* Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session
* Negative BAC and a CIWA score of \< 9 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures
* In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests
* Females with childbearing potential must have a negative serum pregnancy test on the screening visit with a negative urine pregnancy test at randomization and agree to use an effective method of birth control for the study duration and two weeks thereafter.
* Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent
* Willingness to comply with the provisions of the protocol and take daily oral medication
Exclusion Criteria
* GGT more than 3 times the upper limit of normal
* Female subjects with childbearing potential who are pregnant, nursing, or refuse to use an effective method of birth control for the duration of the study and two weeks thereafter
* Meets DSM-V criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders (e.g., cocaine, amphetamines, heroin, PCP) other than alcohol or nicotine
* Has a positive UDS at screening or Visit 3 (laboratory session)
* Treatment within the month prior to screening with an investigational drug, vaccine or drugs that may influence study outcomes, or drugs that may pose a safety risk as determined by the Study Physician.
* History of hypersensitivity to the study drugs or the ingredients
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
The Scripps Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara J. Mason
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara J. Mason, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
The Scripps Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Susan Quello
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AA012602-14A1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.